Trident Texofab Reports Strong Q2 FY26 Performance with 16% Revenue Growth and Margin Expansion

1 min read Updated on 15 Nov 2025, 04:24 PM

Reviewed by

Riya DeyScanX News Team

Overview

Trident Texofab Limited announced strong Q2 FY26 results with revenue from operations growing 16% year-over-year to ₹3,063.46 lakhs. Total income increased 6% to ₹3,102.56 lakhs. EBITDA margin expanded significantly to 8.12% from -1.04% in Q2 FY25. Profit after tax rose 12% to ₹112.77 lakhs. The company's shift towards manufacturing operations continues to drive growth and margin improvement.

*this image is generated using AI for illustrative purposes only.

Trident Texofab Limited announced robust financial results for the second quarter of fiscal year 2026, with significant top-line growth and margin improvement.

Key Highlights

Revenue from operations grew 16% year-over-year to ₹3,063.46 lakhs in Q2 FY26
Total income increased 6% to ₹3,102.56 lakhs
EBITDA margin expanded substantially to 8.12%, up from -1.04% in Q2 FY25
Profit after tax rose 12% to ₹112.77 lakhs

Strong Revenue Growth

Trident Texofab continued its growth momentum, with revenue from operations rising 16% compared to the same quarter last year. Total income for Q2 FY26 stood at ₹3,102.56 lakhs, marking a 6% year-over-year increase.

Significant Margin Expansion

The company reported a notable improvement in profitability, with EBITDA margin expanding to 8.12% in Q2 FY26 from -1.04% in Q2 FY25. This 916 basis point increase reflects enhanced operational efficiency.

Manufacturing Focus Drives Growth

Trident Texofab's shift towards manufacturing operations continues to be a key growth driver. The manufacturing division is now the core strength of the company's business, contributing to both revenue growth and margin improvement.

Management Commentary

The management highlighted the company's healthy financial performance, noting revenue growth on both year-over-year and sequential bases. They emphasized the manufacturing division's role as the core strength of operations and expressed satisfaction with the notable improvement in operating profitability margins.

Outlook

With its continued focus on manufacturing and improved operational metrics, Trident Texofab appears well-positioned for future growth. The company's ability to expand margins while growing revenue indicates strengthening fundamentals in its business model.

Investors will likely watch for sustained margin improvement and further growth in the manufacturing segment in coming quarters as indicators of Trident Texofab's long-term prospects.

Historical Stock Returns for Trident Texofab